Lucky Core Industries Limited (LCI) : 2HFY25 Analyst briefing takeaways - By Insight Research
Feb 13 2025
Insight Securities
- Lucky Core Industries Limited has conducted its 2HFY25 analyst briefing to discuss its financial result and future outlook. We have summarized following key takeaways from the briefing.
- In 1HFY25, LCI revenue from pharma business was ~PKR10.4bn vs. PKR5.8bn in SPLY. The increase is attributable to deregulation of nonessential and integration of Pfizer portfolio. Additionally, the company stated that PKR3.2bn of the total PKR10.4bn revenue came from the Pfizer portfolio. The Pfizer portfolio is expected to contribute approximately PKR8-9bn on an annualized basis in FY25.
- Regarding its pharmaceutical business, the company stated that 65% of its current portfolio consists of nonessential products. In the recently acquired Pfizer portfolio, six out of seven brands fall under the nonessential category
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low